Key result
Chemotherapy rechallenge succeeds without recurrent major events in a case of 5-fluorouracil-induced severe acute myocarditis.
Why the study?
Severe manifestations of fluoropyrimidine cardiotoxicity such as myocarditis are rare, and chemotherapy rechallenge after cardiotoxicity is generally discouraged.
Is chemotherapy rechallenge safe in a patient with prior severe acute 5-fluorouracil-induced myocarditis?
Case Report (n=1)
Is chemotherapy rechallenge safe in a patient with prior severe acute 5-fluorouracil-induced myocarditis?
Chemotherapy rechallenge with 5-fluorouracil may be feasible in carefully selected patients who previously developed severe acute myocarditis, provided there is multidisciplinary cardio-oncology management.
Answers are grounded in this paper and cite their sources.
Multidisciplinary cardio-oncology assessment may allow 5-FU rechallenge after myocarditis; leaves open broader application pending prospective validation.
Background Fluoropyrimidines are among the most common chemotherapeutic agents associated with cardiotoxicity, typically presenting as angina due to coronary vasospasm. Severe manifestations such as myocarditis and cardiogenic shock are rare, and rechallenge after cardiotoxicity is generally discouraged. We report a case of acute 5-fluorouracil–induced myocarditis with successful rechallenge after multidisciplinary evaluation. Case summary A 30-year-old man with unresectable rectal adenocarcinoma developed acute cardiotoxicity during the first FOLFOX-6 cycle, presenting with abdominal pain and palpitations. ECG showed atrial fibrillation and ST-segment elevation. Echocardiography revealed severe biventricular dysfunction with elevated cardiac biomarkers. Coronary angiography excluded obstructive disease, and cardiac magnetic resonance confirmed acute myocarditis with diffuse edema and non-ischaemic late gadolinium enhancement. Guideline-directed heart failure therapy led to rapid functional recovery within days. Following multidisciplinary cardio-oncology assessment, chemotherapy rechallenge under continuous monitoring was performed without recurrence of major adverse events. Subsequent cycles were well tolerated, and follow-up CMR showed preserved ventricular function with residual non-ischaemic LGE. Discussion This case highlights the importance of early recognition of fluoropyrimidine cardiotoxicity, the role of multidisciplinary cardio-oncology management, and the potential feasibility of rechallenge in carefully selected patients.
No takes yet. Share an insight, caveat, or question.
Greco et al. (2026) conducted a case report in 5-fluorouracil-induced acute myocarditis (n=1). 5-fluorouracil (FOLFOX-6) rechallenge was evaluated on Recurrence of major adverse events. A 30-year-old man with 5-fluorouracil-induced severe acute myocarditis successfully underwent chemotherapy rechallenge without recurrence of major adverse events.
Synapse has enriched 10 related papers. Consider them for comparative context: